eligibility_summary
Adults ≥18 with severe eosinophilic asthma (per ERS/ATS) on high‑dose ICS/LABA, already prescribed benralizumab per label/reimbursement, independent of study, able to consent, read instructions, and report PROs q4w and meds weekly. Exclude: interfering study or RCT ≤3 mo, biologic anaphylaxis, asthma biologic ≤6 mo or concurrent, unresolved helminth ≤24 w, other lung disease, limiting comorbidities, most cancers ≤5 y (exceptions), pregnancy/lactation, safety risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Benralizumab (Fasenra) – an afucosylated human IgG1 monoclonal antibody (biologic immunotherapy). Mechanism of action: Binds IL-5 receptor alpha (IL-5Rα/CD125) on eosinophils and basophils, blocking IL-5 signaling and inducing potent antibody-dependent cell-mediated cytotoxicity (ADCC) via NK cells (enhanced FcγRIIIa binding), resulting in near-complete depletion of eosinophils and reduction of eosinophilic airway inflammation and exacerbations. Cells/pathways targeted: IL-5/IL-5R pathway, primary cellular targets are eosinophils, with effects on basophils, engages NK cells to mediate ADCC, modulates type 2 (Th2/eosinophilic) inflammation. Study: Prospective, non-interventional, real-world single-arm study in Germany of adults with severe eosinophilic asthma already prescribed benralizumab.